Hyperbaric oxygen therapy kills the anaerobic bacteria that cause actinomycosis and breaks the cycle of chronic infection
Hyperbaric oxygen therapy kills the anaerobic bacteria that cause actinomycosis and breaks the cycle of chronic infection
Understanding actinomycosis and how HBOT targets the anaerobic conditions that sustain it
Actinomycosis is a chronic suppurative and granulomatous bacterial infection caused primarily by Actinomyces israelii and related species — Gram-positive, filamentous, facultatively anaerobic bacteria that are part of the normal flora of the human mouth, gut and genitourinary tract. Disease occurs when these organisms gain access to deeper tissues through mucosal disruption: dental procedures, trauma, aspiration, surgery or foreign bodies (including intrauterine devices in pelvic actinomycosis).
Actinomycosis manifests in several characteristic forms. Cervicofacial actinomycosis (the most common, accounting for approximately 50% of cases) presents as a slowly enlarging, indurated swelling of the jaw, neck or cheek — often with the characteristic “lumpy jaw” appearance, draining sinuses, and sulfur granules in the discharge. Thoracic actinomycosis involves the lungs and pleura, presenting as chronic pneumonia unresponsive to standard antibiotic courses. Abdominal and pelvic actinomycosis typically follows bowel perforation or appendicitis and presents as an abdominal mass mimicking malignancy.
The pathological hallmark of actinomycosis is the formation of sulfur granules — dense microcolonies of bacteria embedded in a protein matrix that physically protect the organisms from host immune responses and antibiotic penetration. Standard treatment requires prolonged high-dose penicillin or amoxicillin courses (typically 6 to 12 months), but treatment failure and recurrence are common, particularly in cases with extensive fibrosis or deep tissue involvement.
HBOT addresses the fundamental pathophysiology of actinomycosis: the hypoxic, fibrotic tissue environment that sustains anaerobic bacterial survival. By flooding infected tissue with high-pressure oxygen, HBOT creates conditions directly hostile to Actinomyces and reconstitutes the neutrophil oxidative killing capacity that fibrotic, hypoxic tissue has disabled. HBOT also dramatically potentiates antibiotic activity in infected tissue — including in the fibrotic masses where antibiotic penetration is otherwise severely limited.
Insurance coverage: Actinomycosis is a Medicare-approved indication for HBOT, and most commercial insurance companies cover HBOT for this condition when it is used as an adjunct to conventional therapy in patients whose disease is refractory to antibiotics and surgical treatment. Our Patient Care Coordinators will work with you and your insurance company to verify your coverage and facilitate prior authorization.
Slowly enlarging, indurated jaw, neck or cheek mass (cervicofacial) — the classic "lumpy jaw"
Draining sinuses discharging pus containing yellow-white sulfur granules
Chronic pneumonia, chest wall involvement or pleural disease (thoracic)
Abdominal mass, fistula formation or pelvic mass (abdominal/pelvic)
Persistent infection despite standard antibiotic courses
Recurrent infection after apparently successful treatment
How HBOT targets the biology of actinomycosis
Actinomycosis persists through a combination of anaerobic bacterial survival, impaired immune function in fibrotic tissue and protected bacterial colonies. HBOT attacks each of these mechanisms simultaneously.
Directly kills anaerobic Actinomyces bacteria
Restores neutrophil oxidative killing in fibrotic tissue
Dramatically potentiates antibiotic activity
Disrupts sulfur granule microcolonies
Reduces chronic inflammation and fibrosis progression
Supports wound healing after surgical debridement
For Providers
Clinical evidence for HBOT in actinomycosis
Actinomycosis is a rare condition, so large randomized controlled trials of HBOT are not feasible. The evidence base consists of case reports, case series and the strong mechanistic rationale derived from HBOT's well-established activity against anaerobic infections.
Direct anaerobic bactericidal mechanism: Actinomyces israelii and related species are facultative anaerobes — organisms that grow preferentially in low-oxygen environments and are significantly inhibited and killed by elevated oxygen tensions. HBOT at 2.0 to 2.4 ATA raises tissue oxygen partial pressures to levels directly hostile to these organisms, the same mechanism that underlies HBOT's established role in gas gangrene (clostridial myonecrosis) and necrotizing soft tissue infections. This mechanistic rationale is strong and well-supported by the broader anaerobic infection literature.
Neutrophil oxidative killing restoration: The oxidative killing mechanism of neutrophils and macrophages — the primary cellular defense against bacterial infection — requires adequate tissue oxygen to generate the reactive oxygen species used to destroy bacteria. Tissue oxygen tensions in the fibrotic masses of actinomycosis are severely reduced, disabling this immune mechanism. HBOT restores tissue oxygen to levels that fully reconstitute leukocyte bactericidal function. [Mandell GL. J Clin Invest. 1974;54(6):1427–1434. PMID: 4434044]
Antibiotic potentiation: Aminoglycosides and penicillins — antibiotics central to actinomycosis treatment — demonstrate significantly greater bactericidal activity in well-oxygenated tissue. HBOT's restoration of tissue oxygen tension dramatically improves antibiotic activity within the fibrotic masses where drug penetration and efficacy are most compromised. This synergistic mechanism has been demonstrated across multiple anaerobic infection models. [Park MK et al. Antimicrob Agents Chemother. 1991;35(4):762–766. PMID: 1850960]
Case series — refractory cervicofacial actinomycosis: Published case reports and series document resolution of refractory cervicofacial actinomycosis with HBOT added to antibiotic therapy after prolonged courses had failed to achieve resolution. Patients with extensive fibrotic disease, draining sinuses and failure of 6 or more months of penicillin therapy have been reported to achieve complete clinical resolution following HBOT courses of 30 to 40 sessions. [Manheim SD et al. Oral Surg Oral Med Oral Pathol. 1994;77(6):565–568. PMID: 8065726]
Thoracic actinomycosis case reports: HBOT has been reported as a successful adjunct in thoracic actinomycosis cases refractory to prolonged antibiotic therapy, including cases with empyema and chest wall involvement. The improved tissue oxygenation in chronically fibrotic pulmonary tissue is the proposed mechanism for the enhanced antibiotic response observed. The scarcity of published cases reflects the rarity of the condition rather than absence of benefit.
Osteomyelitis parallel: When actinomycosis involves bone — particularly the mandible in cervicofacial disease — HBOT has a particularly strong evidence base. Chronic refractory osteomyelitis is a Medicare-approved HBOT indication, and the mechanism of action in actinomycotic osteomyelitis is identical: restoration of hypoxic bone tissue oxygen, reconstitution of osteoclast and immune function, and potentiation of antibiotics. HBOT is strongly indicated when actinomycosis has involved cortical bone.
Our actinomycosis HBOT protocol at Bay Area Hyperbarics
HBOT for actinomycosis is used as an adjunct to prolonged antibiotic therapy — not as a replacement for it. It is most valuable in refractory, recurrent or extensive disease, and in cases where fibrosis and poor tissue oxygenation are limiting antibiotic effectiveness. We coordinate closely with your infectious disease specialist throughout treatment.
Infectious disease assessment and treatment coordination
Our medical team reviews your actinomycosis diagnosis, anatomical site, antibiotic history, treatment response and imaging. We coordinate with your infectious disease specialist, oral-maxillofacial surgeon or thoracic surgeon to integrate HBOT into your overall treatment plan as a synergistic adjunct to antibiotic therapy.
HBOT sessions to restore tissue oxygenation and kill residual bacteria
You breathe 100% oxygen at 2.0 to 2.4 atmospheres absolute for approximately 90 minutes per session, once daily. Actinomycosis protocols typically involve 20 to 40 sessions as an initial course, with reassessment of clinical and imaging response at completion. Treatment is timed to run concurrently with your antibiotic course for maximum synergistic effect.
Monitoring and long-term recurrence prevention
We track clinical response — reduction in mass size, resolution of draining sinuses, improvement in pain and swelling — throughout the treatment course. Given actinomycosis' tendency to recur, we work with your infectious disease team to plan the full antibiotic duration and discuss maintenance HBOT sessions if residual disease or high recurrence risk is present.
Frequently Asked Questions
Answers to the questions actinomycosis patients and their providers most often ask about hyperbaric oxygen therapy.
Actinomycosis is notoriously difficult to eradicate for several reasons. The dense fibrosis surrounding infection sites limits antibiotic penetration to the bacteria. Sulfur granules physically protect bacterial microcolonies from both antibiotics and immune cells. The chronically hypoxic environment within fibrotic tissue disables neutrophil killing and reduces antibiotic efficacy. And Actinomyces organisms can survive in low-oxygen tissue environments that standard circulation cannot adequately oxygenate. HBOT addresses all of these simultaneously by restoring tissue oxygen to levels that reconstitute immune function and dramatically improve antibiotic activity.
Struggling with refractory actinomycosis? Ask us about HBOT
Bay Area Hyperbarics offers HBOT as an adjunctive therapy for actinomycosis — and because actinomycosis is a Medicare-approved HBOT indication, treatment is covered by Medicare and most commercial insurance plans when conventional therapy has been insufficient. Our Patient Care Coordinators will work with you and your insurance company to verify coverage and facilitate authorization. Call us to schedule a consultation.
